 Eric Prince
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Craniopharyngioma | 8 | 2025 | 77 | 3.450 |
Why?
| | Pituitary Neoplasms | 7 | 2025 | 190 | 2.680 |
Why?
| | Decision Support Systems, Clinical | 2 | 2025 | 269 | 1.310 |
Why?
| | Artificial Intelligence | 2 | 2025 | 381 | 1.240 |
Why?
| | Brain Neoplasms | 8 | 2025 | 1327 | 0.970 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 122 | 0.840 |
Why?
| | Computational Biology | 2 | 2025 | 681 | 0.720 |
Why?
| | Cellular Senescence | 1 | 2024 | 223 | 0.700 |
Why?
| | Machine Learning | 2 | 2025 | 587 | 0.690 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 91 | 0.610 |
Why?
| | Software | 1 | 2025 | 695 | 0.590 |
Why?
| | Cerebellar Neoplasms | 2 | 2020 | 177 | 0.550 |
Why?
| | Medulloblastoma | 2 | 2020 | 215 | 0.540 |
Why?
| | Epilepsy, Temporal Lobe | 1 | 2017 | 38 | 0.510 |
Why?
| | Biomarkers, Tumor | 3 | 2024 | 1319 | 0.510 |
Why?
| | Ependymoma | 4 | 2020 | 176 | 0.510 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 27 | 0.490 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 779 | 0.470 |
Why?
| | Laser Therapy | 1 | 2017 | 140 | 0.460 |
Why?
| | Glioma | 4 | 2025 | 429 | 0.450 |
Why?
| | Transcriptome | 1 | 2020 | 1036 | 0.390 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3888 | 0.320 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2754 | 0.310 |
Why?
| | Brain | 2 | 2022 | 2934 | 0.290 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 79 | 0.280 |
Why?
| | Genes, myc | 2 | 2020 | 51 | 0.280 |
Why?
| | Infratentorial Neoplasms | 2 | 2019 | 71 | 0.260 |
Why?
| | CADASIL | 1 | 2026 | 8 | 0.240 |
Why?
| | KATP Channels | 1 | 2026 | 23 | 0.240 |
Why?
| | Pericytes | 1 | 2026 | 37 | 0.240 |
Why?
| | Microcirculation | 1 | 2026 | 141 | 0.230 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 34 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Child | 10 | 2025 | 22600 | 0.210 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2025 | 1437 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 186 | 0.210 |
Why?
| | Pyrazoles | 2 | 2020 | 512 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2020 | 628 | 0.210 |
Why?
| | Clonal Evolution | 1 | 2024 | 47 | 0.200 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 102 | 0.200 |
Why?
| | Phagocytosis | 1 | 2025 | 296 | 0.200 |
Why?
| | Cerebrovascular Circulation | 1 | 2026 | 289 | 0.200 |
Why?
| | Cell Line, Tumor | 6 | 2025 | 3523 | 0.200 |
Why?
| | Tumor Burden | 1 | 2024 | 324 | 0.190 |
Why?
| | Cerebral Cortex | 1 | 2026 | 470 | 0.190 |
Why?
| | MAP Kinase Signaling System | 1 | 2024 | 306 | 0.180 |
Why?
| | Circle of Willis | 1 | 2022 | 7 | 0.180 |
Why?
| | Humans | 21 | 2025 | 144667 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2024 | 532 | 0.160 |
Why?
| | Preoperative Period | 1 | 2020 | 149 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2024 | 1145 | 0.150 |
Why?
| | Disease Progression | 2 | 2024 | 2847 | 0.150 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 14 | 0.150 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 80 | 0.150 |
Why?
| | Pyrimidinones | 1 | 2020 | 125 | 0.150 |
Why?
| | Cell Survival | 3 | 2017 | 1092 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 222 | 0.140 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 239 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 211 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1496 | 0.130 |
Why?
| | Stereotaxic Techniques | 1 | 2017 | 42 | 0.130 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2201 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 112 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 129 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 357 | 0.130 |
Why?
| | Models, Theoretical | 1 | 2020 | 578 | 0.120 |
Why?
| | Brain Stem Neoplasms | 1 | 2017 | 87 | 0.120 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2020 | 431 | 0.120 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.120 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 164 | 0.120 |
Why?
| | Pteridines | 1 | 2016 | 22 | 0.120 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2016 | 43 | 0.120 |
Why?
| | Urea | 1 | 2016 | 84 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1766 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3147 | 0.120 |
Why?
| | Thiophenes | 1 | 2016 | 121 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 435 | 0.110 |
Why?
| | Disease-Free Survival | 1 | 2016 | 768 | 0.110 |
Why?
| | Cisplatin | 1 | 2016 | 339 | 0.100 |
Why?
| | Disease Models, Animal | 2 | 2026 | 4539 | 0.100 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 967 | 0.100 |
Why?
| | Proto-Oncogene Proteins | 1 | 2016 | 619 | 0.100 |
Why?
| | Algorithms | 1 | 2020 | 1844 | 0.090 |
Why?
| | Apoptosis | 2 | 2019 | 2397 | 0.090 |
Why?
| | Prognosis | 2 | 2019 | 4312 | 0.090 |
Why?
| | Mice | 5 | 2026 | 18261 | 0.080 |
Why?
| | Male | 7 | 2026 | 72431 | 0.070 |
Why?
| | Mice, Transgenic | 2 | 2026 | 2184 | 0.070 |
Why?
| | Animals | 6 | 2026 | 37948 | 0.060 |
Why?
| | Female | 6 | 2024 | 78304 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1961 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | Blood Flow Velocity | 1 | 2026 | 419 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2017 | 2950 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2025 | 2037 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2024 | 223 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2026 | 501 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2017 | 11735 | 0.050 |
Why?
| | beta Catenin | 1 | 2024 | 252 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2019 | 2489 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2026 | 927 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2024 | 17149 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 368 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 197 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 881 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 610 | 0.030 |
Why?
| | Middle Aged | 1 | 2020 | 35971 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 23 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 264 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 33 | 0.030 |
Why?
| | B7-H1 Antigen | 1 | 2020 | 242 | 0.030 |
Why?
| | Quality of Life | 2 | 2020 | 3183 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2017 | 116 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2017 | 190 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 117 | 0.030 |
Why?
| | Child, Preschool | 2 | 2024 | 11790 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 138 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 125 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 224 | 0.030 |
Why?
| | Adult | 1 | 2020 | 40489 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 925 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 820 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1268 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 317 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2026 | 5967 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 372 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2839 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2089 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 595 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2016 | 751 | 0.030 |
Why?
| | Pyrimidines | 1 | 2017 | 519 | 0.030 |
Why?
| | Cohort Studies | 1 | 2024 | 5957 | 0.030 |
Why?
| | DNA Damage | 1 | 2016 | 430 | 0.020 |
Why?
| | Up-Regulation | 1 | 2016 | 848 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2019 | 0.020 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 581 | 0.020 |
Why?
| | Phosphorylation | 1 | 2017 | 1704 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 828 | 0.020 |
Why?
| | Nuclear Proteins | 1 | 2017 | 741 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5414 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1484 | 0.020 |
Why?
| | Transcription Factors | 1 | 2017 | 1726 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5185 | 0.010 |
Why?
| | Infant | 1 | 2019 | 10023 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 22409 | 0.010 |
Why?
|
|
Prince's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|